

WPS Virtual Fall Symposium

What's New?

Treatment Innovations for Today and Tomorrow

Presented by the



and the



4 AMA PRA Category 1 Credits™

September 25, 2021

8:30 am – 1:30 pm

Experts will provide learners with up-to-date information on the latest advances in the treatment of a range of psychiatric disorders. These talks and discussions are designed to change learners' competence, performance, and outcomes by providing them with the latest knowledge that goes beyond formal drug and device labeling, including best approaches to post-acute treatment (e.g. maintenance treatment following a course of transcranial magnetic stimulation), combination interventions, integration of pharmacotherapy and psychotherapy, and stepwise responses to treatment resistance.



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American Psychiatric Association (APA) and the Washington Psychiatric Society. The APA is accredited by the ACCME to provide continuing medical education for physicians. The American Psychiatric Association designates this live activity for a maximum of 4 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Committee Members: Matt Rudorfer, MD, chair; Ann Marie Dietrich, MD; Colleen Blanchfield, MD; Ann Horst, MD; Ifeanyi Olele, DO

Program

8:30 – 8:45 am

Welcome from **Matt Rudorfer, MD**, CME Committee Chair and **Steven Israel, MD**, WPS President

8:45 – 9:20 am

“What’s new in the Treatment of Schizophrenia”

Christoph U. Correll, MD

9:20 – 9:55 am

“What’s New in the Treatment of Child and Adolescent Disorders”

Benedetto Vitiello, MD

9:55 – 10:35 am

Break

10:35 – 11:35 am **Keynote Address**

“Defining the Role of Psychedelics in Clinical Psychiatry”

David Nutt, MD

11:35 am – 12:10 pm

“What’s New in the Treatment of Perinatal Mood Disorders”

Riah Patterson, MD

12:10 pm – 12:45 pm

“What’s New in the Treatment of Bipolar Disorder”

Keming Gao, MD, PhD

12:45 – 1:20 pm

“What’s New in the Treatment of Depression”

Pilar Cristancho, MD

1:20 – 1:30 pm
General Discussion

Educational Objectives

At the conclusion of the program, participants will be able to:

- Evaluate targetable and emerging mechanisms of action and the related brain physiology for medications used for the treatment of schizophrenia.
- Consider the efficacy and safety/tolerability data for medications recently approved and in phase 2/phase 3 trials for the treatment of schizophrenia.
- Utilize medications recently approved for the treatment of individuals with schizophrenia, based on appropriate indications and populations.
- Review recent research reports on the efficacy and safety of psychiatric treatments for children and adolescents.
- Determine the advantages of new clinical science of psychedelic drugs such as psilocybin.
- Define and review perinatal mood and anxiety disorders
- Evaluate the newly FDA-approved treatment for postpartum depression, brexanolone, and review the common side effects and potential benefits.
- Assess the FDA-approved medications for the treatment of different phases of bipolar disorder and review the off-label treatment options.
- Define clinical applications of interventional psychiatry in the treatment of depression.
- Compare the efficacy, side effect burden, and logistic considerations of interventional modalities.
- Discuss the network model of depression and contributions from brain stimulation treatments.

DISCLOSURES

Presenter Disclosures

Dr. Correll's Disclosure

Neither I nor my spouse/partner has any relevant relationship with any commercial interest. (Disclosure on file)

Dr. Vitiello's Disclosure

Neither I nor my spouse/partner has any relevant relationship with any commercial interest. (Disclosure on file)

Dr. Nutt's Disclosure

Neither I nor my spouse/partner has any relevant relationship with any commercial interest. (Disclosure on file)

Dr. Patterson's Disclosure

Neither I nor my spouse/partner has any relevant relationship with any commercial interest. (Disclosure on file)

Dr. Gao's Disclosure

Neither I nor my spouse/partner has any relevant relationship with any commercial interest. (Disclosure on file)

Dr. Cristancho's Disclosure

Neither I nor my spouse/partner has any relevant relationship with any commercial interest. (Disclosure on file)

Disclosure statements of the WPS President and members of the CME Committee

Dr. Isreal's Disclosure

Neither I nor my spouse/partner has any relevant relationship with any commercial interest. (Disclosure on file)

Dr. Rudorfer's Disclosure

Neither I nor my spouse\partner has any relevant relationship with any commercial interest. (Disclosure forms on file.)

Dr. Dietrich's Disclosure

Neither I nor my spouse\partner has any relevant relationship with any commercial interest. (Disclosure forms on file.)

Dr. Blanchfield's Disclosure

Neither I nor my spouse\partner has any relevant relationship with any commercial interest. (Disclosure forms on file.)

Dr. Horst's Disclosure

Neither I nor my spouse\partner has any relevant relationship with any commercial interest. (Disclosure forms on file.)

Dr. Lawson's Disclosure

Neither I nor my spouse\partner has any relevant relationship with any commercial interest. (Disclosure forms on file.)

Dr. Olele's Disclosure

Dr. Olele disclosed that he or his spouse/partner is a Consultant with Myriad Neuroscience. (Disclosure forms on file.)

Target Audience

The program is designed for psychiatrists and behavioral health providers in the Washington, DC area.

Commercial Support

No commercial support has been provided for this event.

Receiving CME/CE Credit

Following the program, you will be emailed a link to the program evaluation. Upon completion of the evaluation you will be provided with a credit certificate.